loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Blinatumomab reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Blinatumomab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 16Blincyto

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Blincyto

    Blinatumomab

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Blincyto

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Amgen

    Blinatumomab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 379

    2019 Revenue in Millions : 312

    Growth (%) : 21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Blincyto

    Blinatumomab

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Blincyto

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Astellas

    Blinatumomab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 40

    2019 Revenue in Millions : 38

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Blincyto

    Blinatumomab

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Blincyto

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Astellas

    Blinatumomab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 49

    2020 Revenue in Millions : 40

    Growth (%) : 32

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Blincyto

    Blinatumomab

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Blincyto

    China
    arrow
    Discovery on Target
    Not Confirmed

    Beigene

    Blinatumomab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 14

    2020 Revenue in Millions : 0

    Growth (%) : 100

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Blincyto

    Blinatumomab

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Blincyto

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Amgen

    Blinatumomab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 472

    2020 Revenue in Millions : 379

    Growth (%) : 25

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Blincyto

    Blinatumomab

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Blincyto

    Japan
    arrow
    Discovery on Target
    Not Confirmed

    Astellas

    Blinatumomab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 58

    2021 Revenue in Millions : 54

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Blincyto

    Blinatumomab

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Blincyto

    China
    arrow
    Discovery on Target
    Not Confirmed

    BeiGene

    Blinatumomab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 38

    2021 Revenue in Millions : 14

    Growth (%) : 176

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Blincyto

    Blinatumomab

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Blincyto

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Amgen

    Blinatumomab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 583

    2021 Revenue in Millions : 472

    Growth (%) : 24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Blincyto

    Blinatumomab

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Blincyto

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Amgen

    Blinatumomab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 861

    2022 Revenue in Millions : 583

    Growth (%) : 48

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Blincyto

    Blinatumomab

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Blincyto

    China
    arrow
    Discovery on Target
    Not Confirmed

    BeiGene

    Blinatumomab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 59

    2022 Revenue in Millions : 38

    Growth (%) : 51

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF